Moleculin Secures Australian Patent for Annamycin Formulation Technology

Bitget2026/11/12 13:38

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Moleculin Biotech secured an Australian patent covering preparation of preliposomal Annamycin lyophilizate, strengthening international protection for its formulation technology.
The patent was granted jointly to the company and The Board of Regents of The University of Texas System.
Annamycin is in clinical development for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120837PRIMZONEFULLFEED9876280) on November 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Moleculin Secures Australian Patent for Annamycin Formulation Technology

You may also like

Crypto prices